Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the…

• BS
  Bristol-Myers Squibb
• EL
  Eli Lilly and Company
• P
  Pfizer
• A
  AstraZeneca
• S
  Sanofi
• LM
  Leona M. and Harry B. Helmsley Charitable Trust
• UO
  University of Virginia
• IC
  Insulet Corporation
• MC
  MannKind Corporation
• D
  Dexcom
• OH
  OPKO Health
• UV
  Universiteit van Amsterdam
• KL
  KU Leuven
• NN
  Novo Nordisk
• RD
  Roche Diabetes Care
• NI
  National Institutes of Health
• UF
  U.S. Food and Drug Administration
• AD
  Abbott Diabetes Care
• NC
  National Cancer Institute
• NI
  National Institute of Diabetes and Digestive and Kidney Diseases